Reference Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

Ref Type
PMID
Authors X. Pivot, I.M. Bondarenko, Z. Nowecki, M. Dvorkin, E. Trishkina, J.H. Ahn, Y. Vinnyk, S-A. Im, T. Sarosiek, S. Chatterjee, M. Wojtukiewicz, V. Moiseyenko, Y. Shparyk, M. Bello III, V. Semiglazov, L. Younju, J. Lim
Title One-year safety, immunogenicity, and survival results from a phase III study comparing SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab in HER2-positive early breast cancer treated with neoadjuvant-adjuvant treatment
URL https://www.annalsofoncology.org/article/S0923-7534(20)37516-5/fulltext
Abstract Text Background: Equivalence for efficacy between SB3 (a proposed trastuzumab biosimilar) and originator trastuzumab (TRZ) in terms of breast pathologic complete response (bpCR) rates has been demonstrated and previously reported.1 Here we present the one-year results on safety, immunogenicity, event-free-survival (EFS), and overall survival (OS). Methods: Study compared neoadjuvant SB3 or TRZ for 8 cycles concurrently with chemotherapy (4 cycles of docetaxel followed by 4 cycles of 5-fluorouracil/epirubicin/cyclophosphamide). Patients then underwent surgery followed by 10 cycles of adjuvant SB3 or TRZ as randomised. The primary endpoint was bpCR rate and secondary endpoints included safety, immunogenicity, EFS, and OS up to the adjuvant period. Results: A total of 875 patients were randomised with a median follow-up duration of 438 days, and 765 patients completed adjuvant therapy (SB3, N = 381; TRZ, N = 384). Incidences of treatment emergent adverse events (TEAEs) were comparable between arms (Table). Most frequently occurring TEAEs were alopecia, neutropenia, and nausea during the neoadjuvant period and radiation skin injury, procedural pain, and fatigue during the adjuvant period. EFS rates were 92.2% in SB3 and 91.6% in TRZ (hazard ratio 0.94; 95% CI, 0.59 to 1.51). There were a total of 6 deaths (SB3, N = 1; TRZ, N = 5). Immunogenicity was low and comparable, with anti-drug antibody positive for 3 patients (0.7%), in each arm.

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
SB3 HER2 (ERBB2) Antibody 72 SB3 is a Herceptin (trastuzumab) biosimilar that binds to Erbb2 (Her2) and induces anti-tumor immune response against Erbb2 (Her2)-positive tumors (Ann Oncol 2017, Vol 28, Suppl 5, Abstract # 153PD).
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References